<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710734</url>
  </required_header>
  <id_info>
    <org_study_id>GU-086</org_study_id>
    <secondary_id>15-1071</secondary_id>
    <nct_id>NCT02710734</nct_id>
  </id_info>
  <brief_title>Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)</brief_title>
  <official_title>A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle&#xD;
      invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT)&#xD;
      sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate,&#xD;
      vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile&#xD;
      and the post AMVAC TURBT findings, patients will be treated with active surveillance&#xD;
      (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We&#xD;
      hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years,&#xD;
      while preserving the bladder and thus quality-of-life for a proportion of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II trial studies how well maximal transurethral surgery (surgery performed with a&#xD;
      special instrument inserted through the urethra) followed by accelerated methotrexate,&#xD;
      vinblastine, doxorubicin hydrochloride, cisplatin, and radiation therapy work in treating&#xD;
      patients with bladder cancer that has spread to the muscle. Drugs used in chemotherapy, such&#xD;
      as methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may&#xD;
      kill more tumor cells. Giving combination chemotherapy and radiation therapy before surgery&#xD;
      may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Actual">June 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival (MFS) at 2 years.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to complete of 3 cycles of neoadjuvant AMVAC and chemoradiation therapy with 5-FU and mitomycin C.</measure>
    <time_frame>Up to 37 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of urothelial carcinoma recurrence in active surveillance patients</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival and PFS of the entire cohort</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>toxicity during each treatment arm according to NCI CTCAE v 4.01 criteria</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with â‰¥cT1 disease after TURBT#2</measure>
    <time_frame>up to 22 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients requiring a cystectomy, either immediately after TURBT#2 or as salvage after surveillance or CRT</measure>
    <time_frame>up to 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Endoscopic Tumor Quantification System score at each TURBT</measure>
    <time_frame>24 months</time_frame>
    <description>At each cystoscopic examination, the location and extent of tumor volume will be visually depicted and graded according to Endoscopic Tumor Quantification System</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life with neoadjuvant AMVAC and subsequent risk-adapted treatment</measure>
    <time_frame>60 months</time_frame>
    <description>American Urologic Association (AUA) Symptom Index Score, Sexual Health Inventory for Men (SHIM) score or Female Sexual Function Index (FSFI) score</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Urothelial Carcinoma of the Bladder</condition>
  <arm_group>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiation therapy (IMRT)</intervention_name>
    <description>2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral Resection of Bladder tumor</intervention_name>
    <description>Performed at before and after AMVAC and after chemoradiation and intravesicle therapy</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Intravenous on day 1 with radiation treatment</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients â‰¥18 years.&#xD;
&#xD;
          -  Primary urothelial or predominantly urothelial carcinoma of the bladder.&#xD;
&#xD;
          -  Histologic evidence of muscularis propria invasion.&#xD;
&#xD;
          -  AJCC27 clinical stage T2-T4a .&#xD;
&#xD;
          -  No radiographic evidence of lymph node positivity (N0) or metastatic disease (M0).&#xD;
             Clinical lymphadenopathy on staging CT greater than 1.5 cm in short axis must be&#xD;
             biopsy proven negative.&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2.&#xD;
&#xD;
          -  Left ventricular ejection fraction â‰¥ 50% by MUGA or ECHO within 6 months of study&#xD;
             entry.&#xD;
&#xD;
          -  Normal organ and bone marrow function as defined:&#xD;
&#xD;
        Leukocytes â‰¥ 3,000/mcL Absolute neutrophil count â‰¥ 1,500/mcL Platelets â‰¥ 100,000/mcL Total&#xD;
        bilirubin â‰¤ institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) â‰¤ 2.5 X&#xD;
        institutional ULN Creatinine Creatinine Clearance â‰¥ 50 mL/min (calculated using the&#xD;
        Cockroft-Gault formula or measured with 24 hour urine collection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any component of small cell histology.&#xD;
&#xD;
          -  Prior pelvic radiation therapy or patients who have undergone prior radiation to&#xD;
             greater than or equal to 25% of the bone marrow within the past year are excluded due&#xD;
             to risk of life threatening myelosuppression&#xD;
&#xD;
          -  Prior systemic chemotherapy; patients who have received any previous systemic&#xD;
             chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy&#xD;
             for another malignancy within 1 year of study entry are ineligible.&#xD;
&#xD;
          -  Prior or concurrent malignancy of any other site except for non-melanoma skin cancer,&#xD;
             unless disease free interval â‰¥ 5 years.&#xD;
&#xD;
          -  Patients who have received experimental agents within 4 weeks of study entry.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used&#xD;
             in the study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection (defined by current oral or intravenous antibiotic therapy), symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Pregnant women are excluded from this study due to the potential for teratogenic or&#xD;
             abortifacient effects of cytotoxic chemotherapy.&#xD;
&#xD;
          -  Known HIV-positive patients on combination antiretroviral therapy are ineligible&#xD;
             because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy.&#xD;
             In addition, these patients are at increased risk of lethal infections when treated&#xD;
             with marrow-suppressive therapy.&#xD;
&#xD;
          -  Patients with hydronephrosis that has not been addressed with an intervention such as&#xD;
             placement of a stent.&#xD;
&#xD;
          -  Pregnancy &amp; Women of Childbearing Potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington Cancer Institute at MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

